We previously reported the isolation of Cache Valley virus (CVV), Kairi virus (KRIV), Cholul virus (CHLV), and South River virus (SOURV) from mosquitoes in the Yucatan Peninsula of Mexico ([@R1]--[@R3]). Antibodies to CVV, CHLV, and SOURV were also detected in livestock in this region ([@R4]). These viruses belong to the genus *Orthobunyavirus* ([@R5]). All viruses in this genus possess a tripartite, single-stranded, negative-sense RNA genome.

CVV is a recognized human pathogen ([@R5]) that has been linked to severe encephalitis and multiorgan failure. KRIV has not been implicated as a cause of human disease, although antibodies to this virus have been detected in humans in Argentina ([@R6]). Recent data suggest that CHLV is a reassortant that acquired its small RNA segment from CVV and medium and large RNA segments from Potosi virus (POTV) ([@R1]). No clear evidence exists for human susceptibility to infection with CHLV or SOURV. However, diagnostic laboratories rarely test for orthobunyavirus infection; therefore, the true disease incidence and seroprevalence of these viruses remains to be determined. Because orthobunyaviruses comprise a neglected but potentially deadly group of viruses and recent studies have provided evidence of orthobunyavirus activity in the Yucatan Peninsula ([@R1]--[@R4]), we investigated whether orthobunyaviruses commonly infect humans in this region.

The Study
=========

Serum samples were obtained from 823 febrile patients at the Secretaria de Salud de Yucatán and other health institutions in Merida during January--October 2007. The patients resided in all 3 states of the Yucatan Peninsula of Mexico: Yucatan (n = 809), Quintana Roo (n = 8) and Campeche (n = 6). The study was approved by the Institutional Biosafety Committees at Iowa State University (Ames, IA, USA) and the Universidad Autónoma de Yucatán (Mérida, Mexico).

All serum samples were examined at a dilution of 1:20 by plaque reduction neutralization test (PRNT) by using CVV (strain CVV-478), and PRNTs were performed as described ([@R7]). A subset of serum samples with antibodies that neutralized CVV were titrated and further analyzed by PRNT by using CVV, CHLV (strain CHLV-Mex07), KRIV (strain KRIV-Mex07), SOURV (strain NJO-94f), Maguari virus (strain BeAr7272), and Wyeomyia virus (strain prototype). All of these viruses belong to the Bunyamwera (BUN) serogroup except SOURV, which belongs to the California (CAL) serogroup.

Titers were expressed as the reciprocal of highest serum dilutions yielding [\>]{.ul}90% reduction in the number of plaques (PRNT~90~). For etiologic diagnosis, the PRNT~90~ antibody titer for each virus was required to be [\>]{.ul}4-fold greater than that to the other viruses tested.

Antibodies that neutralized CVV were detected in 146 (18%) of 823 study participants. The mean ages of patients with and without antibodies that neutralized CVV were 32.0 and 22.3 years, respectively. Logistic regression analysis showed that the risk for infection increased significantly with age (p = 0.0001).

Serum samples from 50 seropositive patients were titrated and analyzed by comparative PRNT to identify the orthobunyaviruses responsible for these infections. Six persons were seropositive for CVV, 5 for CHLV, and 1 for SOURV or a SOURV-like virus; 38 had antibodies to an undetermined orthobunyavirus ([Table](#T1){ref-type="table"}). Because SOURV was the only CAL serogroup virus used in this study, and another CAL serogroup virus may have been responsible for the infection, the person who had a SOURV PRNT~90~ titer [\>]{.ul}4-fold than that to the other viruses tested received a conservative PRNT diagnosis of seropositive for SOURV or a SOURV-like virus. Because interserogroup crossreactivity of neutralizing antibodies to viruses in the BUN and CAL serogroups has not been seen, the 17 persons with antibodies that neutralized SOURV and [\>]{.ul}1 of the BUN serogroup viruses might have been exposed to [\>]{.ul}1 viruses from each serogroup.

###### Endpoint titers of serum samples collected from persons in Mexico and analyzed by using comparative PRNT\*

  Patient ID no.   Demographic characteristics          PRNT~90~ titers   Diagnosis                                  
  ---------------- ----------------------------- ------ ----------------- ----------- ------- ----- ----- ----- ---- ---------------------------
  28               Yucatan                       18/M                     80          20      --    --    40    --   UND
  34               Yucatan                       39/F                     80          20      --    --    20    --   CVV
  52               Quintana Roo                  39/F                     160         --      --    40    80    --   UND
  54               Yucatan                       32/M                     40          20      --    --    40    --   UND
  62               Yucatan                       44/M                     40          --      --    20    20    --   UND
  72               Yucatan                       23/M                     80          --      --    --    40    --   UND
  81               Yucatan                       60/F                     20          20      --    20    --    --   UND
  92               Yucatan                       13/M                     160         20      --    20    80    --   UND
  93               Yucatan                       42/F                     40          20      --    --    20    --   UND
  113              Yucatan                       24/F                     20          --      --    --    --    --   UND
  114              Yucatan                       29/F                     40          --      --    --    20    --   UND
  120              Yucatan                       60/F                     20          --      --    320   --    --   SOURV or SOURV-like virus
  159              Yucatan                       54/M                     20          --      --    --    20    --   UND
  161              Yucatan                       53/M                     20          20      --    --    --    --   UND
  163              Yucatan                       27/F                     160         80      40    --    40    --   UND
  167              Yucatan                       16/M                     160         --      --    --    40    --   CVV
  183              Yucatan                       69/F                     20          --      --    --    20    --   UND
  184              Yucatan                       34/M                     160         40      --    --    80    --   UND
  185              Yucatan                       25/F                     20          --      --    --    --    --   UND
  192              Campeche                      54/F                     80          40      --    --    20    --   UND
  193              Yucatan                       16/F                     80          --      --    --    20    --   CVV
  194              Yucatan                       69/F                     20          --      --    20    --    --   UND
  200              Yucatan                       3/F                      40          --      --    40    40    --   UND
  205              Yucatan                       53/M                     40          --      --    20    20    --   UND
  208              Yucatan                       57/F                     20          160     --    --    --    --   CHLV
  210              Yucatan                       42/M                     20          --      --    --    20    --   UND
  224              Yucatan                       34/M                     20          20      --    20    --    --   UND
  234              Yucatan                       39/F                     20          80      --    --    20    --   CHLV
  236              Yucatan                       74/F                     20          --      --    20    --    --   UND
  386              Yucatan                       14/F                     20          --      --    20    --    --   UND
  388              Yucatan                       60/M                     160         1,280   160   --    40    --   CHLV
  389              Yucatan                       5/M                      20          --      --    20    --    --   UND
  390              Yucatan                       33/M                     40          20      40    20    40    --   UND
  392              Yucatan                       22/M                     20          --      --    --    --    --   UND
  393              Yucatan                       29/M                     40          20      --    --    40    --   UND
  396              Yucatan                       34/F                     80          --      --    --    20    --   CVV
  397              Yucatan                       32/M                     80          --      --    --    40    --   UND
  399              Yucatan                       27/M                     320         1,280   160   --    320   --   CHLV
  400              Yucatan                       37/F                     20          --      --    --    --    --   UND
  401              Yucatan                       30/F                     160         --      --    --    40    --   CVV
  402              Yucatan                       18/M                     20          --      --    --    20    --   UND
  403              Yucatan                       50/F                     20          20      --    --    --    --   UND
  407              Yucatan                       27/M                     80          20      --    --    40    --   UND
  408              Yucatan                       40/F                     20          --      --    --    --    --   UND
  412              Yucatan                       60/M                     20          320     80    40    40    --   CHLV
  415              Yucatan                       17/F                     20          --      --    20    --    --   UND
  420              Yucatan                       16/F                     160         --      --    --    20    --   CVV
  429              Yucatan                       37/F                     20          --      --    --    --    --   UND
  442              Yucatan                       10/F                     20          40      --    20    --    --   UND
  455              Yucatan                       30/F                     20          --      --    20    20    --   UND

\*PRNT, plaque reduction neutralization test; CVV, Cache Valley virus; CHLV, Cholul virus; KRIV, Kairi virus; SOURV, South River virus; MAGV, Maguari virus, WYOV, Wyeomyia virus; --, titer \<20; UND, undetermined orthobunyavirus.

CHLV and POTV share the same medium RNA segment, so antibodies for these viruses cannot be differentiated by PRNT. Furthermore, antibodies to CHLV and POTV cannot be differentiated by complement fixation test ([@R4]). Thus, we cannot dismiss POTV as a possible cause of infection in some or all of the study participants who were seropositive for CHLV. However, it appears more likely that these persons had been infected with CHLV because this virus has been isolated in the Yucatan Peninsula, whereas no direct evidence has been found for POTV in this region.

As already noted, serum samples from 38 (76%) of the study participants analyzed by comparative PRNT had antibodies to an undetermined orthobunyavirus. Most of these persons had low PRNT~90~ titers; the highest PRNT~90~ titer for 29 of these persons did not exceed 40. Because neutralizing antibody levels decline over time, these findings may indicate that many of these infections occurred years ago, and the trace amounts of neutralizing antibodies that remained were insufficient to yield a [\>]{.ul}4-fold difference between the titers of the virus responsible for the infection and the other viruses used in the PRNTs. Another explanation is that some of these persons had been infected with an orthobunyavirus not included in the PRNTs, although all orthobunyaviruses known to occur in the Yucatan Peninsula were represented.

Conclusions
===========

We found 18% of the 823 Yucatan residents participating in our study had evidence of orthobunyavirus exposure. This number is presumably an underestimate; additional seropositive persons might have been identified if the initial PRNTs had not been restricted to CVV. In particular, additional seropositive persons likely would have been detected if SOURV was used in the initial PRNTs, because a screening algorithm that includes only a BUN serogroup virus would likely miss many CAL serogroup virus infections. Nevertheless, we provide evidence that orthobunyaviruses commonly infect humans in the Yucatan Peninsula.

Previous serosurveys have provided information on the seroprevalence of orthobunyaviruses in humans in the United States. For example, antibodies that neutralized CVV were detected in 42/356 (12%) residents in Maryland and Virginia in 1961--1963 ([@R8]). Antibodies that neutralized Maguari virus or Tensaw virus were detected in 71/≈300 humans in Florida in the 1980s ([@R9]); as observed in our study, the highest PRNT titers for most of the seropositive persons in that study did not exceed 40.

All persons in our study cohort initially sought care for unspecified fever; however, we could not determine whether any of these febrile illnesses were a direct consequence of orthobunyavirus infection. The detection of acute orthobunyavirus infections is limited because no IgM-capture ELISA for orthobunyavirus diagnosis exists. PRNTs can be used to identify recent orthobunyavirus infections when paired acute and convalescent serum samples are available, but for our study, only single serum samples were available from each participant. Orthobunyavirus viremias in humans are transient and of low magnitude, which makes reverse transcription PCR ineffective for the detection of orthobunyavirus RNA in serum samples. However, a duplex reverse transcription PCR was recently developed for the detection of CVV RNA in human cerebrospinal fluid ([@R10]).

In conclusion, we provide evidence that orthobunyaviruses commonly infect humans in the Yucatan Peninsula. These viruses are also a common cause of infection of livestock in this region ([@R4]). Our findings underscore the need to determine whether orthobunyaviruses represent an unrecognized cause of illness in humans and vertebrate animals in Mexico.
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